Alpine Woods Capital Investors LLC Buys 9,697 Shares of Kenvue Inc. $KVUE

Alpine Woods Capital Investors LLC increased its stake in Kenvue Inc. (NYSE:KVUE) by 3.7% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 271,822 shares of the company’s stock after buying an additional 9,697 shares during the period. Kenvue accounts for 1.4% of Alpine Woods Capital Investors LLC’s portfolio, making the stock its 22nd largest position. Alpine Woods Capital Investors LLC’s holdings in Kenvue were worth $5,689,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors also recently bought and sold shares of KVUE. Pittenger & Anderson Inc. purchased a new position in Kenvue during the 1st quarter valued at about $30,000. Trust Co. of Vermont grew its stake in shares of Kenvue by 266.8% in the second quarter. Trust Co. of Vermont now owns 1,581 shares of the company’s stock worth $33,000 after acquiring an additional 1,150 shares during the period. TruNorth Capital Management LLC bought a new stake in shares of Kenvue in the first quarter worth approximately $36,000. Truvestments Capital LLC bought a new stake in shares of Kenvue in the first quarter worth approximately $37,000. Finally, Clal Insurance Enterprises Holdings Ltd boosted its holdings in shares of Kenvue by 378.5% in the first quarter. Clal Insurance Enterprises Holdings Ltd now owns 1,627 shares of the company’s stock worth $39,000 after buying an additional 1,287 shares during the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research firms recently issued reports on KVUE. Evercore ISI dropped their price objective on shares of Kenvue from $23.00 to $18.00 and set an “in-line” rating on the stock in a report on Tuesday, September 23rd. Rothschild & Co Redburn raised shares of Kenvue from a “neutral” rating to a “buy” rating and dropped their price objective for the stock from $22.50 to $22.00 in a report on Friday, September 26th. Canaccord Genuity Group dropped their price objective on shares of Kenvue from $29.00 to $26.00 and set a “buy” rating on the stock in a report on Friday, August 8th. Rothschild Redb raised shares of Kenvue from a “hold” rating to a “strong-buy” rating in a report on Friday, September 26th. Finally, Citigroup dropped their price objective on shares of Kenvue from $20.00 to $17.00 and set a “neutral” rating on the stock in a report on Thursday, October 9th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, nine have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $21.18.

Kenvue Price Performance

KVUE stock opened at $16.21 on Tuesday. Kenvue Inc. has a one year low of $15.47 and a one year high of $25.17. The company’s fifty day moving average price is $19.03 and its 200-day moving average price is $21.25. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.68 and a current ratio of 0.98. The company has a market capitalization of $31.10 billion, a PE ratio of 21.90, a price-to-earnings-growth ratio of 2.39 and a beta of 0.72.

Kenvue (NYSE:KVUE) last released its earnings results on Thursday, August 7th. The company reported $0.29 EPS for the quarter, topping the consensus estimate of $0.28 by $0.01. Kenvue had a net margin of 9.37% and a return on equity of 20.06%. The firm had revenue of $3.84 billion for the quarter, compared to the consensus estimate of $3.94 billion. During the same quarter in the previous year, the firm earned $0.32 earnings per share. The company’s quarterly revenue was down 4.0% compared to the same quarter last year. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. On average, equities analysts anticipate that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, August 27th. Investors of record on Wednesday, August 13th were given a $0.2075 dividend. This is a boost from Kenvue’s previous quarterly dividend of $0.21. This represents a $0.83 annualized dividend and a yield of 5.1%. The ex-dividend date was Wednesday, August 13th. Kenvue’s dividend payout ratio (DPR) is presently 112.16%.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.